SAFETY NOTICE

EZETIMIBE 10 mg TABLETS and LOSARTAN POTASSIUM 50 mg TABLETS

Sandoz Inc. has determined that the cap and bottle combination for particular lots of Ezetimibe 10 mg tablets and Losartan Potassium 50 mg tablets in the U.S. is not child-resistant, posing a risk of harm if the tablets are swallowed by children.

Sandoz Inc. is voluntarily recalling the listed lots of these medicines to provide child-resistant replacement caps to patients, because Sandoz Inc. has determined that the cap and bottle combination does not meet U.S. child-resistant packaging requirements.

There are no quality or safety issues with the medications for their intended use.

Product Description	Lot Number
EZETIMIBE 10 mg Tablets 30 Count Bottle NDC Number 0781-5690-31	JE4491 JE4492 JE4493 JE4495 JG0308 JG0310 JG0311 JG0312 JG5061 JG5063 JK8921 JK8922 JK8923 JK8924 JL5535 JM2253 JM2254 JM2255 JM2257 JM2258 JM2259 JM5986 JM5987
EZETIMIBE 10 mg Tablets 30 Count Bottle NDC Number 0781-5690-92	JE4481 JG0249 JK8989 JN0764
LOSARTAN 50 mg Tablets 30 Count Bottle NDC Number 0781-5701-31	HV9471

What do patients need to do?

1. **Immediately secure this medicine so that it is out of the sight and reach of children.**
2. **Continue taking your medicine as prescribed, as there are no safety or quality issues with the medicine itself.**
3. **Please contact Sandoz at 1-800-525-8747 to request a child-resistant replacement cap.**

We appreciate your immediate attention and cooperation and apologize for this situation.

Please report any adverse events by calling Sandoz at 1-800-525-8747 or by emailing Sandoz at qa.drugsafety@sandoz.com. Adverse events can also be reported to FDA online at www.fda.gov/medwatch/report.htm.

Post until December 31, 2019
In cooperation with the U.S. Consumer Product Safety Commission

SANDOZ A Novartis Division